NEULAND LABORATORIES LIMITED

Neuland's Q3 FY 16 Results Conference Call at 4.30 pm IST on February 3,2016

Hyderabad, January 25, 2016 – Neuland Laboratories Ltd., (NSE: NEULANDLAB; BSE:524558), a pharmaceutical manufacturer providing active pharmaceutical ingredients (APIs), complex intermediates and custom manufacturing solutions services to customers located in close to 80 countries, will announce results for the third quarter ending December 2015, financial year ending March 31, 2016 after the Board meeting on February 3, 2016. Following the announcement, the management of the Company will host **earnings call** to discuss the Company's financial performance as per the details below.

Earnings Call Details:

Date	**Wednesday 3rd February, 2016**
Time	**4:30PM to 5:30PM**
Conference Dial-in Numbers	
Primary Number	+91 22 3960 0644
Secondary Number	+91 22 6746 4144
Add to Calendar | Pre- Register for Pass	
The numbers listed above are universally accessible from all networks and all countries	
Local Access Numbers	6000 1221 (Ahmedabad, Bangalore, Bhubaneswar, Chandigarh, Chennai, Coimbatore, Delhi, Goa, Guntur, Gurgaon, Hyderabad, Indore, Jamshedpur, Kanpur, Kochi/Cochin, Kolhapur, Kolkata, Nagpur, Noida, Patna, Pune, Raipur, Rajkot, Surat, Trivandrum, Vadodara, Vijayawada. Accessible from all major carriers except BSNL/MTNL.) 3940 3977 (Available in - Ahmedabad, Bangalore, Chandigarh, Chennai, Gurgaon (NCR), Hyderabad, Kochi/Cochin, Kolkata, Lucknow, Pune. Accessible from all carriers)
Toll Free Numbers	**Hong Kong:** 800 964 448 **Singapore:** 800 101 2045 **UK:** 0 808 101 1573 **USA:** 1 866 746 2133
Neuland Participants	Mr. Davuluri Sucheth Rao, Whole Time Director & CEO Mr. Davuluri Saharsh Rao, Whole Time Director & President of Contract Research Mr. Anil Kumar, CFO

Participants are requested to log in 10 minutes prior to the start of the scheduled call.

NEULAND LABORATORIES LIMITED

About Neuland Labs

For over 30 years, Neuland Labs has been at the forefront of manufacturing APIs through its cGMP manufacturing facilities, working with customers in close to 80 countries. Neuland Labs has developed more than 300 processes and 75 APIs, and it has filed around 48 U.S. drug master files (DMFs) and a total of around 400 DMFs in the European Union (EU) and other countries. Its manufacturing facilities are inspected and approved by the U.S. FDA and other leading regulatory agencies. Its record of quality manufacturing and reliability is highlighted by cGMP certifications that include the U.S. FDA, TGA (Australia), EDQM (EU), German Health Authority, Anvisa (Brazil), EMA (EU), Cofepris (Mexico), KFDA (Korea), PMDA (Japan), ISO 9001, ISO14001, OHSAS18001 and ISO 27001. For more information, visit www.NeulandLabs.com.

For further information, please contact:

Arpita Poola	**Ankit Gupta**
Corp Planning and Communication, Neuland Labs	Christensen Investor Relations
Ph: +91 40 3021 1600	Ph: +91 22 4215 0210
Email: arpita@neulandlabs.com	Email: ankitgupta@christensenir.com

Disclaimer: *Certain of the statements that may be made or discussed at the conference call may be forward-looking statements and/or based on management's current expectations and beliefs concerning future developments and their potential effects upon Neuland and its subsidiaries/ associates. There can be no assurance that future developments affecting Neuland and its subsidiaries / associates will be those anticipated by management. These forward-looking statements are not a guarantee of future performance and involve risks and uncertainties and there are important factors that could cause actual results to differ, possibly materially, from expectations reflected in such forward-looking statements. Neuland does not intend, and is under no obligation, to update any particular forward-looking statement made at the conference call.*